KOL Programs in Medtech and Biotech: What Compliance Allows
By Virgo PR Editorial Team. Reviewed by Kyle Porter, Executive Vice President & Managing Director.
Updated November 21, 2026

What a compliant KOL program looks like in medtech and biotech: AdvaMed consulting rules, the OIG speaker program alert, the Biogen and Novartis settlements, FDA promotion limits and disclosure.
KOL programs in medtech and biotech are compliant when a company documents why it needs the expert, pays fair market value under a written agreement, keeps compensation unrelated to prescribing or purchasing, and reports the payment. Speaker programs draw the most enforcement attention. Biotech companies also may not describe an unapproved drug as safe or effective. The rules and the cases behind them follow.
What makes a KOL program compliant in medtech and biotech?
A compliant KOL program meets six documented conditions drawn from the AdvaMed Code of Ethics and from federal payment reporting law. AdvaMed is the medical technology trade association, and its code is voluntary. The current version took effect on June 1, 2022, according to a Deloitte summary of the AdvaMed Code.
The code says it does not replace laws, regulations or stricter codes. Membership is therefore not a safe harbor, and drug and biologic makers face the same federal statutes even though the code is written for device companies.
ConditionWhat the company must doSource
Legitimate needIdentify the specific service it requires before choosing any expertAdvaMed Code Fair market valuePay an arm's-length price set by objective, documented criteria, never by the volume or value of the expert's businessAdvaMed Code Written agreementDescribe every service and the compensation in a contractAdvaMed Code DocumentationKeep records of how need and fair market value were determinedAdvaMed Code Sales separationKeep sales staff from controlling or unduly influencing who is hiredAdvaMed Code Payment reportingReport payments to physicians, non-physician practitioners and teaching hospitals to CMSPhysician Payments Sunshine Act
One more rule sits beside the table. The Medical Device and Diagnostic Industry article "Crossing the Line: Kickbacks Come Under Increased Government Scrutiny" says consultants should be selected for their expertise, not for their purchasing or prescribing habits. That rule is why the selection record matters as much as the fee.
Why do speaker programs carry the highest legal risk?
Speaker programs carry the highest legal risk because the HHS Office of Inspector General warned on November 16, 2020 that they carry inherent fraud and abuse risks under the federal Anti-Kickback Statute. The agency defined speaker programs as company-sponsored events at which a health care professional gives a presentation to other professionals about a drug or device.
Law firm summaries note that the notice was the first OIG Special Fraud Alert since 2014. The OIG said the sponsoring company, the paid speaker and the attendees may all face increased scrutiny. The alert itself adds that payments for training speakers can raise the same risks. The agency also said it did not intend to discourage meaningful professional training and education.
Two settlements show what the scrutiny can cost. Novartis settled speaker program allegations for $678 million in 2020 and entered a corporate integrity agreement, according to a Skadden analysis of the OIG alert.
The Department of Justice announced a $900 million settlement with Biogen on September 26, 2022. The government alleged that Biogen paid speaker honoraria, speaker training fees, consulting fees and meals to physicians between January 2009 and March 2014 to induce prescriptions of Avonex, Tysabri and Tecfidera. Biogen did not admit wrongdoing, and it paid about $843.8 million to the federal government and $56.2 million to 15 states, Fierce Pharma reported.
Both matters involved ordinary-looking activity: dinners, honoraria and consulting. The problem, as the government described it, was the link between the payments and prescribing.
What can a biotech say about a KOL's view of an unapproved drug?
A biotech may share accurate scientific information about an investigational drug but may not represent in a promotional context that the drug is safe or effective for the use under investigation. That limit comes from 21 CFR 312.7(a) in the Code of Federal Regulations, Part 312.
The rule applies to a sponsor, an investigator and anyone acting on their behalf. The regulation also says it is not meant to restrict the full exchange of scientific information. A conservative reading treats a physician quoted in the sponsor's own press release or website copy as acting on the sponsor's behalf, so that quote should be handled as company speech and reviewed by counsel.
FDA enforces this limit. Its Office of Prescription Drug Promotion sent an untitled letter on November 1, 2019 to the sponsor of an investigational brain cancer drug. The sponsor's corporate website had paired survival figures with statements that the antibodies were safe and effective, according to an Arnall Golden Gregory summary. Describing study results accurately was acceptable. Concluding that the drug works was not.
The same wording discipline applies to every KOL quote. Teams can compare their drafts with the FDA communications rules for biotech and with six real examples in biotech topline data releases.
When must a KOL disclose a financial tie to a company?
A KOL must disclose a financial tie when the audience would not expect it and the tie could change how much weight the audience gives the endorsement, and the company must separately report the payment to CMS. The FTC set the first standard in its Endorsement Guides, codified at 16 CFR Part 255.
The FTC finalized the updated Guides on June 29, 2023. They define a clear and conspicuous disclosure as one that is difficult to miss and easily understandable by ordinary consumers, according to a Hall Render review. The FTC also indicated that a platform's built-in paid partnership label may not be enough on its own.
The second standard is public reporting. Open Payments, run by CMS under the Physician Payments Sunshine Act, collects payments from drug, device and biologic manufacturers to physicians and teaching hospitals. Since 2021 it also covers non-physician practitioners such as physician assistants and nurse practitioners. Payments fall into three categories: general payments, research payments, and ownership or investment interests. For program year 2025, CMS data show $14.67 billion in reported payments and interests, tied to 667,898 physicians and 1,327 teaching hospitals. The CMS Open Payments overview explains who reports and who is covered.
A KOL who speaks to the press or posts online should assume the company payment will be searchable by name. Disclosing it first removes the surprise.
How can a communications team run a KOL program step by step?
A communications team can run a KOL program in seven steps that put the documentation ahead of the first public appearance. This page describes public rules and cases and is not legal advice, so counsel should approve each step.
-
Write the business need in one paragraph before any expert is contacted, naming the service the company lacks.
-
Select experts for their training and experience, and exclude any decision based on who prescribes or buys the product.
-
Set the fee with a documented fair market value method, using an outside valuation expert when the company has no internal benchmark.
-
Sign the written agreement before work starts, listing each service, the hours expected and the rate.
-
Keep sales staff out of expert selection, and let medical affairs or communications make the choice.
-
Review every public statement against the FDA record and the investigational drug rules, then confirm that the wording describes data and does not conclude that a drug is safe or effective.
-
Add a plain disclosure of the company relationship to every interview, post and presentation, and keep a log that finance can match to the annual Open Payments report.
Before any KOL is contacted, ask counsel to approve the written need statement and the fee method. Those two documents answer most of what an auditor or journalist will ask first.
Teams that also run advocate networks can compare structures in tech influencer relations programs, which cover Microsoft, AWS, Google, GitHub, Docker and Oracle. Clinical-stage companies can pair this process with the clinical-stage biotech PR rules.
Frequently asked questions
Are speaker programs illegal?
Speaker programs are not illegal by definition, but the OIG treats them as high risk under the Anti-Kickback Statute. The agency said its November 2020 alert was not meant to discourage meaningful training and education, and it listed suspect characteristics that raise risk when a program looks like payment for prescribing.
Do payments to nurse practitioners get reported?
Payments to nurse practitioners and physician assistants are reported to Open Payments for data collected since 2021, unless the practitioner is an employee of the reporting company. CMS calls these recipients non-physician practitioners, and the program also covers teaching hospitals.
Can a biotech quote a physician on trial results?
A biotech can quote a physician who describes trial results accurately and with context. The quote cannot conclude that an investigational drug is safe or effective, because 21 CFR 312.7(a) bars that claim in a promotional context.
Does the AdvaMed Code replace the law?
The AdvaMed Code does not replace laws, regulations or stricter codes. It is a voluntary standard for medical technology companies, and the Anti-Kickback Statute, FDA rules and FTC guidance apply whether or not a company follows it.
Follow us
LinkedIn





